Xilio Therapeutics, Inc. (XLO) Institutional Ownership

Ownership Summary

Xilio Therapeutics, Inc. (NASDAQ:XLO) appears in 37 institutional 13F filings for the quarter ending December 2025.

• Their combined ownership stood at 27.6% of outstanding shares in December 2025, up from 15.2% in September 2025.
• Their total shares held in XLO increased 102.61% from the prior quarter, while the number of investors in Xilio Therapeutics increased 5.71% year over year.
• Of these 37 funds, 16 grew their exposure to Xilio Therapeutics, 5 cut back, and 16 maintained positions.
• Institutional investors collectively held 39.73Mn shares in Xilio Therapeutics as of December 2025, up by 20.12Mn shares quarter on quarter, and up 12.77Mn shares year over year.
• Gilead Sciences, Inc. leads ownership in XLO with 9.11Mn shares as of December 31, 2025, equal to 6.32% of outstanding shares.
• The most significant purchases of XLO for the quarter ending December 2025 came from Frazier Life Sciences Management, L.P. (5.92Mn), Point72 Asset Management, L.P. (4.0Mn), Bain Capital Life Sciences Investors, LLC (2.81Mn), Sio Capital Management, LLC (2.13Mn), STEMPOINT CAPITAL LP (2.03Mn).
• The biggest sellers of Xilio Therapeutics for the quarter ending December 2025 included Morgan Stanley (122.07K), TWO SIGMA INVESTMENTS, LP (25.76K), UBS Group AG (13.45K), LPL Financial LLC (10.0K), Bank Of America Corp /De/ (231).
• Per Business Quant data, the top 10 holders of Xilio Therapeutics for the quarter ending December 2025 are Gilead Sciences, Inc. (9.11Mn), Bain Capital Life Sciences Investors, LLC (7.37Mn), Frazier Life Sciences Management, L.P. (5.92Mn), Point72 Asset Management, L.P. (4.0Mn), Sio Capital Management, LLC (2.13Mn), STEMPOINT CAPITAL LP (2.03Mn), Merck & Co., Inc. (1.48Mn), VANGUARD GROUP INC (1.26Mn), Empery Asset Management, LP (1.18Mn), Ghisallo Capital Management LLC (1.11Mn).